1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,338 | 0,352 | 10:23 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.06. | Boule Diagnostics AB: Boule Diagnostics appoints new Chief Executive Officer | 601 | GlobeNewswire (Europe) | The Board of Directors at Boule Diagnostics has today appointed Johan Folkunger, Chief Executive Officer, effective June 22, 2026. Johan Folkunger succeeds Simonetta Tumbiolo, who has been serving... ► Artikel lesen | |
| 29.05. | Boule Diagnostics AB: Interim CEO at Boule Diagnostics | 140 | GlobeNewswire (Europe) | The board of directors at Boule Diagnostics has today appointed Simonetta Tumbiolo, currently Chief Commercial Officer Diagnostic, as Interim Chief Executive Officer, effective June 1 2026. As previously... ► Artikel lesen | |
| 13.05. | Boule Diagnostics AB: Bulletin from the Annual General Meeting May 13, 2026 in Boule Diagnostics | 238 | GlobeNewswire (Europe) | At the Annual General Meeting 2026 (the "AGM") it was resolved to adopt the balance sheets and profit and loss statements for the parent company and the group for the financial year 2025. The AGM resolved... ► Artikel lesen | |
| 28.04. | Boule Diagnostics AB: Boule Diagnostics Interim Report Q1 2026 | 153 | GlobeNewswire (Europe) | Stable start to 2026
Quarter January-March 2026} Net sales amounted to SEK 101.6 million (112.9), corresponding to a decrease of 10.0 percent. Organic sales growth amounted to 3.0 percent, currency... ► Artikel lesen | |
| 11.02. | Boule Diagnostics AB: Boule Diagnostics Year-end report 2025 | 328 | GlobeNewswire (Europe) | Improved operating cash flowQuarter October-December 2025Net sales amounted to SEK 120.2 million (143.2), corresponding to a decrease of 16.0 percent. Organic sales growth amounted to -11.7 percent... ► Artikel lesen | |
| 30.12.25 | Boule Diagnostics AB: Boule Diagnostics appoints Michael af Winklerfelt as new CFO | 347 | GlobeNewswire (Europe) | Boule Diagnostics AB appoints Michael af Winklerfelt as new CFO, effective February 2026. Michael af Winklerfelt brings extensive international experience from senior finance roles in pharmaceuticals... ► Artikel lesen | |
| 22.12.25 | Boule Diagnostics AB: Boule Diagnostics Selected as One of Three Providers in Nationwide Hematology Tender in Italy | 181 | GlobeNewswire (Europe) | Boule Diagnostics, together with its Italian distribution partner A. Menarini Diagnostics, is proud to announce its selection as one of only three providers in a nationwide tender for hematology solutions... ► Artikel lesen | |
| BOULE DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 05.12.25 | Boule Diagnostics AB: Boule Diagnostics Announces CEO Transition as Organization Prepares for Next Chapter | 208 | GlobeNewswire (Europe) | Boule Diagnostics today announced that Torben Nielsen, Chief Executive Officer, has decided to leave the company to pursue another professional opportunity. Under Torben's leadership, the company has... ► Artikel lesen | |
| 24.10.25 | Boule Diagnostics AB: Boule Diagnostics Interim Report Q3 2025 | 272 | GlobeNewswire (Europe) | Back to organic growth Quarter July-September 2025Net sales amounted to SEK 127.2 million (130.4), corresponding to a decrease of 2.4 percent. Organic sales growth amounted to 1.7 percent, currency... ► Artikel lesen | |
| 13.10.25 | Boule Diagnostics AB: Boule Diagnostics Announces CFO Departure for New Opportunity | 192 | GlobeNewswire (Europe) | Boule Diagnostics today announced that Holger Lembrér, Chief Financial Officer, will be leaving the company to pursue a new professional opportunity outside the organization.Torben Nielsen, CEO of Boule... ► Artikel lesen | |
| 18.07.25 | Boule Diagnostics AB: Boule Diagnostics Interim Report Q2 2025 | 469 | GlobeNewswire (Europe) | Strong instrument sales Quarter April-June 2025Net sales amounted to SEK 129.3 million (137.0), corresponding to a decrease of 5.6 percent. Organic sales growth amounted to -3.3 percent, currency effects... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRIGHTSPRING HEALTH SERVICES | 69,68 | +0,01 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P MidCap 400 and Karman Holdings to Join S&P SmallCap 600 | NEW YORK, July 14, 2026 /PRNewswire/ -- S&P SmallCap 600 constituent BrightSpring Health Services Inc. (NASD: BTSG) will replace Chart Industries Inc. (NYSE: GTLS)... ► Artikel lesen | |
| BILLIONTOONE | 124,59 | -0,22 % | BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,210 | +0,05 % | Kaplan Fox & Kilsheimer LLP: Kaplan Fox Alerts Investors of Alignment Healthcare, Inc. (ALHC) to an Investigation of Potential Securities Law Violations | New York, New York--(Newsfile Corp. - July 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. ("Alignment Healthcare" or... ► Artikel lesen | |
| BETA BIONICS | 16,860 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance | IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| GENEDX | 62,37 | -0,10 % | Piper Sandler raises GeneDx stock price target on coverage policy | ||
| HEARTFLOW | 25,500 | +0,04 % | Heartflow, Inc.: New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management | ||
| ADAPTHEALTH | 10,190 | 0,00 % | AdaptHealth Flags Material Breach After Threat Actor Accessed Patient Management Systems | ||
| PROCEPT BIOROBOTICS | 19,300 | -0,05 % | PROCEPT BioRobotics to Report Second Quarter 2026 Financial Results on August 4th, 2026 | ||
| PROGYNY | 32,360 | 0,00 % | KeyBanc raises Progyny stock price target on utilization strength | ||
| LIFESTANCE HEALTH GROUP | 10,795 | +0,05 % | LifeStance Health Group, Inc.: LifeStance Reports First Quarter 2026 Results | SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial results... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 34,070 | -0,64 % | JPMORGAN stuft Siemens Healthineers auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Siemens Healthineers von 55,80 auf 54,30 Euro gesenkt, aber die Einstufung auf "Overweight" belassen. David Adlington passte seine... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 28,030 | 0,00 % | Privia Health Group, Inc.: Privia Health Reports First Quarter 2026 Financial Results | Strong First Quarter Performance and Operating ExecutionReiterated Full-Year 2026 Guidance Reflects Continued Momentum ARLINGTON, Va., May 07, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq:... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 41,490 | -2,15 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 9,350 | +0,11 % | Aveanna Healthcare Holdings, Inc: Aveanna Healthcare Holdings Completes Acquisition of Family First Homecare and Updates Full Year 2026 Guidance | ATLANTA, June 02, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient... ► Artikel lesen | |
| FRESENIUS | 41,080 | +0,15 % | DAX-Rekordjagd beendet - DHL Group, Fresenius, Rheinmetall, SAP und Talanx im Check | Die Rekordjagd im DAX ist zur Wochenmitte erst einmal beendet. Gewinnmitnahmen nach dem jüngsten Hochlauf, erneute Schwäche bei KI- und Halbleiterwerten sowie schwache Vorgaben aus Asien bremsen die... ► Artikel lesen |
BOULE DIAGNOSTICS AB gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell -0,72 % bei einem Aktienkurs von 0,345 Euro. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BOULE DIAGNOSTICS AB finden Sie auf Wallstreet Online.